Australia markets closed

InspireMD, Inc. (NSPR)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.3300+0.0500 (+2.19%)
At close: 04:00PM EDT
2.2300 -0.07 (-3.04%)
Pre-market: 08:46AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.2800
Bid0.0000 x 0
Ask2.3500 x 100
Day's range2.2800 - 2.3800
52-week range1.5800 - 3.8500
Avg. volume34,709
Market cap58.086M
Beta (5Y monthly)0.93
PE ratio (TTM)N/A
EPS (TTM)-0.8200
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.50
  • GlobeNewswire

    InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

    - Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime has been accepted for presentation at LINC 2024, to be held May 28-31 - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s CGUARDIANS II clinical trial for Transcarotid Artery Revascularization (TCAR), as well a

  • Simply Wall St.

    InspireMD Insider Ups Holding By 13% During Year

    Insiders were net buyers of InspireMD, Inc.'s ( NASDAQ:NSPR ) stock during the past year. That is, insiders bought more...

  • GlobeNewswire

    InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

    -Conference call and webcast to be held at 8:30 a.m. EDT-TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open. Management will host a conference call and webcast with the investment community at 8:30